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Abstract
Background: Canine hip dysplasia (CHD) is a common disease, with a complex genetic background. Dogs with
severe CHD sometimes also suffer from osteoarthritis (OA), an inflammatory, often painful and incurable condition.
Previous studies have reported breed-specific genetic loci associated with different hip dysplasia and OA
phenotypes. However, the independent replication of the known associations within or across breeds has been
difficult due to variable phenotype measures, inadequate sample sizes and the existence of population specific
variants.
Results: We execute a validation study of 46 genetic markers in a cohort of nearly 1600 dogs from ten different
breeds. We categorize the dogs into cases and controls according to the hip scoring system defined by the
Fédération Cynologique Internationale (FCI). We validate 21 different loci associated on fourteen chromosomes.
Twenty of these associated with CHD in specific breeds, whereas one locus is unique to the across-breed study. We
show that genes involved in the neddylation pathway are enriched among the genes in the validated loci.
Neddylation contributes to many cellular functions including inflammation.
Conclusions: Our study successfully replicates many loci and highlights the complex genetic architecture of CHD.
Further characterisation of the associated loci could reveal CHD-relevant genes and pathways for improved
understanding of the disease pathogenesis.
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Background
Revealing the genetic background of canine hip dysplasia
(CHD) has remained one of the biggest veterinary co-
nundrums in the past few decades. Although there has
been a lot of effort to uncover risk loci and causal vari-
ants, their validation and replication has proven difficult.
An inadequate sample size has been an issue in many
studies but studies have also been hampered by the
complexity and inaccuracy of the phenotypes, and an ap-
parent genetic heterogeneity across breeds.
The prevalence of CHD is highly variable between
breed groups and individual breeds. For example, in
USA and Canada, where dogs scored within the Ameri-
can Veterinary Medical Association system, the extreme
values vary from a zero disease prevalence in Italian
Greyhounds to a high prevalence of 77.7% in the
Bulldogs [1]. Consequently, it is important to find both
the genetic factors that are breed-specific and those that
are shared between breeds. Validation of breed-specific
loci is a tedious effort, since one needs to collect a ro-
bustly phenotyped independent cohort of each breed. It
is usually easier to collect a large multi-breed cohort that
can be used to define which CHD associated loci are
shared between breeds. The accuracy of the studied phe-
notypes is imperative. The Finnish Kennel Club (FKC)
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implements the hip scoring system defined by the
Fédération Cynologique Internationale (FCI) [2], and
uses only few specialised veterinarians to evaluate the
hip scores, therefore reducing the inter-observer bias [3].
The single nucleotide polymorphic genetic markers
(SNPs) evaluated in this study have been associated with
CHD by us and others over the past ten years. Zhou et al.
(2010) identified a total of six SNPs in their association
study of Norberg angle (a measure of hip joint laxity) and
OA in several breeds [4]. Friedenberg et al. (2011) found a
homozygous deletion haplotype (intronic to Fibrillin 2;
FBN2) associated with a severe form of CHD in Labrador
Retrievers, as well as in 14 other breeds and in a cross-
bred (Labrador Retriever - Greyhound) dog cohort [5].
Pfahler and Distl (2012) conducted a genome-wide associ-
ation study (GWAS) of the FCI hip score in Bernese
Mountain dogs and found three significantly associated
SNPs representing two different loci [6]. Fels and Distl
(2014) carried out a validation study with the FCI hip
score in the German Shepherd [7]. They reported three
significantly associated SNPs from canine chromosomes
CFA24, CFA26, and CFA34 [7]. Fels et al. (2014) uncov-
ered novel SNPs in previously identified quantitative trait
loci (QTL) and found that nine SNPs in five loci associ-
ated significantly with the FCI hip score in their German
Shepherd cohort [8]. Lavrijsen et al. (2014) used GWAS
and exon sequencing to identify multiple alleles associated
with the FCI hip score in Dutch Labrador Retrievers [9].
Sanchez-Molano et al. (2014) also studied Labrador Re-
trievers using a hip score defined by the British Veterinary
Association and the Kennel Club; they revealed two sig-
nificantly associated QTL including several SNPs [10].
Bartolome et al. (2015) reported a genetic predictive
model for CHD based on seven SNPs they found using
GWAS and candidate gene approaches in Labrador Re-
trievers [11]. Additional markers were provided by our
collaborator at Genoscoper Laboratories [12]. Our own
previous case-control GWAS of the FCI hip score in Ger-
man Shepherds [13] revealed loci on CFA1 and CFA9 that
harboured markers with either risk or protective alleles.
This study aimed to validate the previously reported
associations to better understand their significance and
overall genetic heterogeneity of CHD. We selected 52
SNPs based on prior research, and carried out across-
and within breeds replication studies in nearly 1600 dogs
from 10 breeds. We successfully replicated five markers
across breeds and identified 20 markers in different
breeds, which highlights the heterogeneous genetic
architecture of CHD.
Results
We genotyped 52 SNPs that have previously been associ-
ated with CHD (Additional files 1 and 2), and carried
out various case-control association analyses of CHD
using an independent cohort of 1607 dogs consisting of
10 breeds. After quality control 46 SNPs and 1570 dogs
(751 cases and 819 controls, 666 males and 904 females)
remained for our analyses. The variant data of the 46
SNPs in our cohort are available through the European
Variation Archive (https://www.ebi.ac.uk/eva). These
SNPs are referred to by their ssIDs in this paper (see
Additional file 1). We used the FCI hip score to
categorize dogs into cases (hip score C or worse on both
joints) and controls (hip score A/A). Dogs with hip score
B were excluded to minimize phenotype ambiguity be-
cause although considered normal the FCI hip score B
represents a borderline normal phenotype. We used the
Cochran-Mantel-Haenszel 2x2xK (CMH) test for the
breed-stratified data in our analyses.
Four SNPs associated with CHD across breeds
The raw P-values, the empirical P-values from the per-
mutation procedure, and odds ratios (OR) from the
across-breed CMH test as implemented in PLINK [14]
are shown in Table 1. Only the markers with a signifi-
cant association to CHD, and which also passed a test of
homogeneity of OR across the breeds (see Methods), are
reported. A total of four SNPs associated significantly
with CHD in the across-breed analysis (Table 1). The
markers are located on CFA1, CFA14, CFA26, and
CFA37. Of these, the SNP on CFA1 is from our previous
study of the FCI hip score on German Shepherds [13].
The variant ss7212922135 on CFA14 was originally asso-
ciated with the FCI hip score in Bernese Mountain dogs
[6]. On CFA26, ss7212922151 originally associated with
the FCI hip score in German Shepherds [7], as did
ss7212922122 on CFA33 [8]. The variant ss7212922139
on CFA37 originally associated with OA in a multi-
breed analysis [4]. In contrast to the other four markers,
ss7212922139 in CFA37 was not significantly associated
with CHD in any of the breed-specific analyses.
Within-breed analyses reveal additional markers
The definition of cases and controls was the same as it
was in the across-breed analysis. We used two methods,
basic association analysis by X2-test of allele frequencies
and logistic regression, to assess breed-specific associ-
ation of the SNPs to CHD. The analysis method that
demonstrated a better model fit, as evaluated by visual
examination of quantile-quantile (Q-Q) plots (see Add-
itional file 3), was chosen for each breed. Logistic regres-
sion showed better model fit for five breeds and the
basic association test for the other five (see Additional
file 3). Some inflation of the expected versus observed P-
values was observed in three breeds: Finnish Lapphund,
Golden Retriever, and Labrador Retriever (see Additional
file 3). All these breeds have at least partially separated
breeding lines of herding/working dogs (meaning
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restricted mixing of the breeding dogs between lines),
which may be the source for the inflation.
The within-breed analyses showed multiple significant
associations for different SNPs per breed (Table 2). The
number of significantly associated SNPs varied between
breeds, ranging from none in Bernese Mountain dogs to
six significant associations in the Labrador Retrievers
(Table 2). In total, 22 SNPs on CFA1, CFA3, CFA8,
CFA11, CFA12, CFA14, CFA17, CFA21, CFA24, CFA25,
CFA26, CFA33, and CFA34 demonstrated significant
associations to CHD (Table 2). Six SNPs were significant in
more than one breed (ss7212922122, ss7212922151,
ss7212922154, ss7212922155, ss7212922161, ss7212922163
Table 2). These six SNPs are located on CFA33, CFA26,
CFA34, CFA11, CFA1, and CFA24. The marker
ss7212922155 on CFA11 was significant on three breeds
(Table 2).
ss7212922126 and ss7212922153 on CFA1, as well as
ss7212922156 and ss7212922152 on CFA8 were in high
linkage disequilibrium (r2 > 0.80) and therefore these
Table 1 SNPs demonstrating significant association to CHD in the across-breed CMH test for stratified data








Origins of the SNP (study, breeds,
and phenotypes)
ss7212922120 CFA1: 45382633 A/C 7.4 × 10–03 8.4 × 10–03 1.30 [1.07–1.57] Mikkola et al. (2019) [13]/ German
Shepherd / FCI hip score
ss7212922135 CFA14: 56572744 T/C 0.027 0.028 1.19 [1.02–1.38] Pfahler & Distl (2012) [6]/ Bernese
Mountain dog / FCI hip score
ss7212922151 CFA26: 14157064 T/C 8.8 × 10–03 0.011 1.26 [1.06–1.49] Fels & Distl (2014) [7]/ German
Shepherd/ FCI hip score
ss7212922139 CFA37: 14299531 C/A 0.030 0.032 0.84 [0.72–0.98] Zhou et al. (2010) [4]/ Multiple
breeds and breed crosses/ OA
CI confidence interval; OR odds ratio. The odds ratios and their 95% confidence intervals were calculated by PLINK using default settings in which the minor allele
increases the risk when OR > 1. The reference genome used in this study is CanFam3.1
Table 2 SNPs demonstrating significant association with CHD in nined different breeds



































0.013 / 0.021 a
6.8 × 10–03 / 9.7 × 10–03 a
0.013 / 0.012 a
0.019 / 0.021 a
















0.014 / 0.013 b
0.037 / 0.033 b
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0.025 / 0.040 a











3.2 × 10–03 / 7.3 × 10–03 a
0.029 / 0.033 a










0.017 / 0.014 b











0.016 / 0.017 b































0.046 / 0.037 b
0.030 / 0.023 b
0.027 / 0.020 b
0.016 / 0.017 b
0.029 / 0.023 b
0.040 / 0.027 b




















0.025 / 0.019 b
0.041 / 0.035 b
0.041 / 0.035 b
3.9 × 10–03 / 4.3 × 10–03 b
Finnish Hound (102) ss7212922123 CFA17: 45022358 [4] T/G 2.38 [1.31–4.34] 4.1 × 10–03 / 8.7 × 10–03 a
aX2-test. bLogistic regression. CI confidence interval; OR odds ratio. The odds ratios and their confidence intervals were calculated by PLINK using default settings
in which the minor allele increases the risk when OR > 1. The reference genome used in this study is CanFam3.1. cNo significant associations were observed in
Bernese Mountain dogs. dMajor/minor allele designation of ss7212922120 is changed in Lagotto Romagnolo cohort
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SNP pairs were interpreted to represent one locus each.
Thus, the 22 markers associating with CHD and with
OR’s deviating from 1 represent 20 different loci on 13
chromosomes (Table 2).
Enrichment of the neddylation-pathway
Our across and within breed analyses highlighted
altogether 21 loci on fourteen chromosomes. These loci
contain hundreds of candidate genes and we wanted to
understand whether they are enriched in any cellular
pathways. We performed two analyses using the Search
Tool for the Retrieval of Interacting Genes/Proteins
(STRING) searching for the dog genes/proteins [15], in-
cluding all the positional candidate genes within 1Mb of
the associated SNPs. In the first analysis, no enriched
pathways were detected among the 58 positional candi-
date genes from the across-breed study (see Add-
itional File 4). For the second analysis, we pooled all the
272 positional candidate genes from the across and
within breed studies (Additional File 4). An enrichment
in the neddylation pathway (Reactome ID: CFA-
8951664) was spotted by STRING with a false discovery
rate of 0.0314 (12 observed genes / 220 genes in the
neddylation-pathway gene set, see Fig. 1 and Table 3).
Discussion
Previous efforts by us and others have discovered tens of
loci associating with CHD across breeds. However, the
significance of these findings has remained vague due to
the lack of proper replication because of the variability
of the phenotypes, varied study approaches and inad-
equate sample sizes.
Our replication study in over 1600 dogs across 10
breeds with 52 reported CHD markers validates 21 loci
on fourteen chromosomes. Five loci were associated
across breeds. Two loci included more than one vali-
dated marker. Inclusion of more markers in the study
would have made the validation of each locus more ro-
bust and possibly allowed further selection of associated
loci by the presence of clusters of validated SNPs. Also,
Fig. 1 The protein network of the positional candidate genes from all of the 21 loci. Each circle represents one protein. Red circles indicate
proteins that belong to the neddylation pathway. The lines between circles indicate the evidence for the association between proteins. The
thicker the line, the stronger the evidence. The total number of nodes is 263. For the complete STRING analysis,
see https://version-11-0.string-db.org/cgi/network.pl?networkId=5Sqk4IV9gi5b
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after our analyses several interesting markers were pub-
lished [16].
In total, the replicated loci include over 250 genes with
an enrichment of candidate genes in a neddylation
pathway. Neddylation contributes to various cellular
functions, including inflammation, commonly found in
CHD and OA. Collectively, these results highlight the
complex genetic background of CHD and provide im-
portant insights to the significance of the common and
breed-specific loci in CHD. This helps to prioritize loci
for further studies to identify causal variants and suggest
a novel hypothesis for the possible contribution of the
affected neddylation pathway to CHD and OA.
Four loci on CFA1, CFA14, CFA26, and CFA37
associated with CHD across breeds. The variants
ss7212922118 and ss7212922120 on CFA1 were reported
by us to associate with CHD in German Shepherds [13].
These SNPs locate within and upstream of NADPH Oxi-
dase 3 (NOX3), which is a catalyst for the formation of
superoxides and other reactive oxygen species. NADPH
oxidases are an essential part of a reaction chain that has
been suggested to contribute to the initiation of articular
cartilage degradation [17]. However, NOX3 is mainly
expressed in the inner ear and foetal tissues, which
leaves its role in CHD equivocal.
The SNP on CFA14 (ss7212922135) was originally re-
ported to associate with CHD in Bernese Mountain dogs
[6]. This SNP did not associate with CHD in our Bern-
ese Mountain dog cohort, which may result from differ-
ent case definition between the current and the earlier
study. The variant ss7212922135 originated from a study
cohort where all cases (N = 33) had mild CHD (FCI
score C) [6], while our Bernese Mountain dog cases rep-
resented mild-to-severe CHD based on FCI hip scoring
(Ncases = 88; 42 with mild (FCI score C), 40 with moder-
ate (FCI score D), and six with severe (FCI score E)
CHD). However, ss7212922135 was significant in the
across-breed analysis. This SNP lies within the ninth in-
tron of Cortactin Binding Protein 2 encoding gene
(CTTNBP2) [6]. CTTNBP2 participates in brain develop-
ment and the regulation of synapse organisation. Al-
though no obvious connection was found between this
gene and CHD in the original study [6], some more re-
cent phenotype associations have been listed in the
GWAS catalogue (https://www.ebi.ac.uk/gwas/home) for
CTTNBP2 that are worth noting: juvenile idiopathic
arthritis and idiopathic osteonecrosis of the femoral
head. Furthermore, body mass index adjusted waist-hip
ratio, a measure for storage fat in humans, is listed in
the GWAS catalogue [18] for ST7, WNT2, ASZ1, and
CFTR, all within ±1Mb of ss7212922135. Obesity is a
known environmental risk factor for hip dysplasia and
OA in both dogs and humans [19], although the mech-
anism is still poorly understood. Finally, we want to
highlight the gene encoding Wnt Family Member 2
(WNT2) ~ 401 kb downstream ss7212922135. Wnt sig-
nalling pathways have been shown to participate in joint
development, cartilage maintenance homeostasis, and
the development and progression of OA [20].
Variant ss7212922151 on CFA26 was the third SNP,
which demonstrated significant association to CHD in
the across-breed analysis. This SNP originates from an
Table 3 Enriched candidate genes in the neddylation-pathway
Gene Location in CanFam3.1 Position of the associated marker(s) within
the chromosome (locus; distance from the gene)
ASB7 CFA3: 40365515–40415345 CFA3: 40302288; 63.227 kb
PSMC6 CFA8: 28914302–28947854 CFA8: 28489064; 425.238 kb
CFA8: 28489547; 424.755 kb
FBXO10 CFA11: 53833335–53885416 CFA11: 29908777; 23,924.558 kb
CFA11: 54489194; 603.778 kb
DCAF10 CFA11: 54107165–54150058 CFA11: 29908777; 24,198.388. kb
CFA11: 54489194; 339.136 kb
ASB4 CFA14: 20733592–20794394 CFA14: 20864104; 69.710 kb
CFA14: 56572744; 35,778.350 kb
ASB18 CFA25: 47026112–47087245 CFA25: 47983231; 895.986 kb
COPS8 CFA25: 47783241–47796806 CFA25: 47983231; 186.425 kb
UBE2F CFA25: 48503866–48558950 CFA25: 47983231; 520.635 kb
ASB1 CFA25: 48834475–48870290a CFA25: 47983231; 851.244 kb
FBXW8 CFA26: 13520605–13640975 CFA26: 14157064; 516.089 kb
FBXO21 CFA26: 13722301–13769273 CFA26: 14157064; 387.791 kb
WSB2 CFA26: 14440035–14456158 CFA26: 14157064; 282.971 kb
aASB1 coordinates were derived from the Ensembl database (ENSCAFG00000012461, https://www.ensembl.org). Other coordinates were retrieved from the
National Center for Biotechnology Information database (NCBI)
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association study of CHD in German Shepherds and lo-
cates within the fifth intron of Kinase Suppressor Of Ras
2 encoding gene (KSR2) [7]. KSR2, a scaffolding protein
in the Ras-Raf-MEK-ERK pathway, has been associated
with obesity in mice and humans [21, 22]. Although the
non-SMAD-dependent TGF-β/BMP signalling in the
osteoblastic lineage involves MKK3/6 and p38 [23], we
are not aware of any studies reporting on their inter-
action with KSRs. Another gene of interest in the same
locus is Nitric Oxide Synthase 1 (NOS1; ~ 262 kb away
from ss7212922151). A large variety of different pheno-
types have been reported in Nos1 murine models, in-
cluding abnormal skeletal and skeletal muscle
phenotypes for Nos1tm1Plh-mutants [24].
ss7212922122 on CFA33 locates within the gene en-
coding PEST Proteolytic Signal Containing Nuclear Pro-
tein (PCNP), and was originally found to associate with
CHD in German Shepherds [8]. PCNP expression is
omnipresent in different tissues, and with its ubiquitina-
tion partner Np95/ICBP90-like RING finger protein
(NIRF) it may be involved in a signalling pathway of cell
cycle regulation and/or genome stability [25, 26].
ss7212922122 is also about 469 kb upstream from ABI
Family Member 3 Binding Protein (ABI3BP), which is a
collagen and glycosaminoglycan binding molecule and an
extracellular matrix structural component. Moreover, an
intron variant of ABI3BP (rs9828061) has been associated
with joint hypermobility measurement in humans [27].
Lastly, ss7212922139 on CFA37 locates within the first
intron of Neuropilin 2 (NRP2). It was the only marker
that despite not being significantly associated with CHD
in any particular breed was still significantly associated
with CHD in the across-breed analysis. Indeed, this SNP
originated from a study, which utilised association and
linkage populations of multiple breeds and their crosses
[4]. In our study the marker had OR < 1, indicating pro-
tective effect. The original study did not report ORs, and
the SNP associated with OA [4]. Although the current
study data did not contain the direct OA phenotypes,
OA is nevertheless assessed and considered when deter-
mining the FCI score. Considering the original and
current study, ss7212922139 could represent a genuine
“across-breed locus” for CHD and OA. Zhou et al.
(2010) suggested Par-3 Family Cell Polarity Regulator
Beta (PARD3B) as a candidate gene due to its associ-
ation with OA of the knee in humans [4, 28]. In addition
to PARD3B, NRP2 could also be a plausible candidate
for OA. Neuropilin 2 is as a co-receptor for vascular
endothelial growth factors (VEGFs) [29]. Increased
VEGF expression has been indicated to associate with
increased severity of OA [30], and a functional study
demonstrated that VEGF injections into knee joints of
mice induced OA [31]. Moreover, VEGF and its recep-
tors have been studied as targets for treatment of OA
[32], and an experimental study of a VEGF antibody
(rhu-Mab-VEGF; Bevacizumab or Avastin®) has shown
that Bevacizumab could offer a potential therapy for OA
[33]. However, it remains unknown how NRP2-VEGF
interaction could affect the development and progres-
sion of OA in dogs.
The current within-breed analyses revealed a multi-
tude of loci that associated with CHD, strengthening the
hypothesis that CHD has a complex genetic architecture
and distinct genetic backgrounds in different breeds.
The highest number of associated SNPs was found with
Labrador Retriever (6), while none of the tested markers
associated with CHD in our Bernese Mountain dog co-
hort. The associated markers and loci varied between
breeds. Some SNPs demonstrated association to CHD in
more than one breed and ss7212922151 on CFA26 was
also significant in the across-breed analysis. We want to
acknowledge here that the results in the Finnish Lap-
phund, Golden Retriever and Labrador Retriever breeds
are inflated due to possible population stratification (as
evidenced by the Q-Q plots, see Additional file 3). These
breeds have both show and working/herding lines, which
we could not account for in this study due to the miss-
ing line information. Thus, the breed-specific results for
these three breeds should be regarded with some
caution.
Some of the significant markers from the within-breed
analyses had notably higher or lower ORs (Tables 1 and
2), which is probably due to higher across-breed vari-
ation for these markers. Also, worth noting was that
some breeds had ORs of over 5 for certain markers
(Table 2), which indicates relatively strong association to
the disease outcome for such a complex disorder. Future
studies should concentrate on these loci for breeds such
as the Great Dane that had OR of 5.07 for ss7212922133
on CFA14, and had no marked inflation observed (see
Additional file 3, plots M and N).
This study replicated altogether 21 loci with over 250
potential candidate genes raising an interesting question
of the possible relationship and enrichment of the candi-
date genes in the associated loci predisposing to CHD.
The STRING analysis revealed that the candidate genes
were enriched in a single pathway, neddylation, which is
a ubiquitination-like conserved post-translational protein
modification process [34]. The key actor in neddylation
is NEDD8, which is conjugated to its substrates with the
help of enzymes E1 (activation of NEDD8; NAE1-UBA3
heterodimer), E2 (conjugation; UBE2M or UBE2F), and
E3 (ligase; RBX1 or RBX2) [35]. Neddylation modifies
the biochemical properties of the target substrates [34],
such as many members of the cullin-family, p53, or
EGFR [35, 36]. Neddylation is essential for cell cycle
progression [37, 38], and it has been linked to many
pathologies, especially to human cancers [36, 37].
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Neddylation was recently linked to inflammatory arth-
ritis via increased NF-κB activation, although increased
expression of neddylation-related genes (NEDD8 and
CUL1) were observed only in the synovium of the
rheumatic arthritis and not in the controls with non-
inflammatory OA [39].
Interestingly, searching the STRING database with the 12
neddylation pathway associated candidate genes from the
current study (Table 3) and with 14 genes (CYBA, MAPK14,
MMP2, MMP9, NCF1, NCF2, NCF4, NOX3, NOXA1,
NTN1, RAC1, RAC1, TRIO, VCAM1) highlighted in our pre-
vious studies on CHD on German Shepherds [13, 40] pro-
duced two gene clusters that shared 12 genes associated with
Class I MHC mediated antigen processing & presentation
(R-CFA-983169, https://version-11-0b.string-db.org/cgi/
network?networkId=bPwtieGk6WuV, and Additional file 5).
There is cumulating evidence that inflammatory
mechanisms are active in OA [41, 42]. Neddylation is
demonstrated to participate in regulation of i.a. T-cell
and macrophage functions during inflammation [39, 43,
44]. Both T-cell and macrophage mediated inflammatory
responses have been observed in OA [42, 45], and there-
fore, the possible role of neddylation-pathway in the im-
mune base of OA should be explored further.
Conclusions
We replicate 21 previously reported CHD-associated loci
on fourteen chromosomes and identify neddylation as a
novel candidate pathway for CHD and OA. We identify
common and breed-specific loci and highlight the com-
plex genetic architecture of CHD. Identification of the
causal genes and variants in the associated loci remains
as an important future task to better understand the mo-
lecular pathogenesis of CHD and its subtraits towards
improved treatment and diagnostic options.
Methods
Study cohorts and phenotype
We used SNP genotyping to validate 52 SNPs on several
chromosomes in a large cohort comprising of ten
breeds. Our cohort consisted of 1607 dogs with FCI hip
scores (Table 4), which were used to categorize dogs
into cases (hip score C or worse on both joints, N = 772)
and controls (hip score A/A, N = 835). It is worth noting
that the FCI scoring does not represent a quantitative
phenotype. Furthermore, the distribution of phenotype
categories of the cohort is very skewed and does not
meet the assumptions required for the analysis of data-
sets in the ordinary scale. Because of these reasons, only
case-control analysis was possible. To minimize pheno-
type ambiguity, dogs with hips scored B were excluded.
Although score B is considered normal, it nevertheless
represents a borderline normal phenotype.
The participating breeds were (in order of number of
samples per breed): Finnish Lapphund, Golden Retriever,
Lagotto Romagnolo, Bernese Mountain dog, Samoyed,
Spanish Water dog, Great Dane, Labrador Retriever, Ka-
relian Bear dog, and Finnish Hound. These breeds were
chosen for the project because the prevalence of CHD in
them is at least moderate. FKC collects FCI hip scoring
data into an open-access breeding database from which
the phenotypes were gathered for this study [2, 46]. We
investigated the prevalence of CHD in the above-
mentioned breeds as the mean of observed yearly preva-
lences including all cases from FCI hip score C to E,
measured in an eleven-year period (2006–2016, year of
birth) [2, 46]. The lowest mean prevalence was observed
for Labrador Retriever (19%) and the Finnish Hound
(28%) [46]. Finnish Lapphund, Golden Retriever,
Samoyed, Spanish Water dog, and Great Dane all had a
mean prevalence of CHD between 30 and 40% during this
time period [46]. The highest mean prevalence was
Table 4 Number of dogs and SNPs per breed before and after quality control
Breed Number of dogs before breed-specific
QC (N cases/N controls)
Number of dogs after breed-specific
QC (N cases/N controls)
SNPs after breed-
specific QC
Finnish Lapphund 307 (155/152) 303 (153/150) 48
Golden Retriever 244 (84/160) 236 (79/156) 47
Lagotto Romagnolo 200 (100/100) 194 (96/98) 48
Bernese Mountain dog 172 (94/78) 164 (89/75) 48
Samoyed 150 (72/78) 149 (71/78) 48
Spanish Water dog 114 (56/58) 114 (56/58) 49
Great Dane 114 (57/57) 113 (57/56) 50
Labrador Retriever 102 (55/47) 100 (54/46) 48
Karelian Bear dog 102 (49/53) 97 (47/50) 49
Finnish Hound 102 (50/52) 102 (50/52) 49
Total quantity 1607 (772/835) 1572 (753/819) –
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observed for the Karelian Bear dog (41%), Bernese Moun-
tain dog (43%), and Lagotto Romagnolo (45%) [46].
To minimise possible genomic stratification and sub-
sequent inflation of the test statistics we were careful
not to incorporate close relatives and included only one
individual from all core-families during the initial data
collection. Nevertheless, more distant relatedness may
exist within the breeds. Also, Finnish Lapphund, Golden
Retriever and Labrador Retriever are breeds that have
working/herding breeding lines, which are at least par-
tially separate from the rest of the breeding dogs. In the
current study we did not have the breeding line informa-
tion for these dogs and could not account for it in the
analyses. This may cause additional inflation of the test
statistics due to stratification within the breed. The
breed-specific results for these three breeds must there-
fore be interpreted with some caution.
SNP genotyping
Agena MassARRAY® iPLEX was used to genotype 52
SNPs (Additional files 1 and 2) in 1607 dogs from ten
breeds. Six of the SNPs were chosen for the project from
our own study in German Shepherds [13]. Ten markers
from CFA1, CFA5, CFA8, CFA20, and CFA25 were se-
lected based on investigations by Wisdom Health. These
markers are included in a patent (Patent no.:
US10150998B2 [12]) and five of them were also in
Lavrijsen et al. (2014) [9]. The rest of the markers were
chosen from earlier studies of Zhou et al. (2010) [4],
Friedenberg et al. (2011) [5], Pfahler and Distl (2012) [6],
Bartolome et al. (2015) [11], Fels and Distl (2014) [7],
Fels et al. (2014) [8], and Sanchez-Molano et al. (2014)
[10] to evaluate whether results were replicable in our
data set. Data from the previous studies (breed, size of
cohort and reported raw and corrected P-values) are
summarized for each marker in Additional file 1.
The genotyping was performed by the Institute of Mo-
lecular Medicine Finland (FIMM) Technology Centre,
University of Helsinki. The genotyping was done in two
separate batches; the first batch included samples from
breeds Labrador Retriever, Golden Retriever, and Bern-
ese Mountain Dog; the second batch included samples
from breeds Spanish Water Dog, Karelian Bear Dog,
Lagotto Romagnolo, Finnish Hound, Samoyed, Finnish
Lapphund, and Great Dane. Initial quality control of
data was carried out in FIMM. In the first batch one
sample was discarded due to success rates lower than
70%, and four SNP assays were discarded due to unreli-
able or no results. In the second batch, five samples were
discarded due to success rates lower than 70%, and two
SNP assays were discarded due to unreliable or no re-
sults. The resulting data were delivered to us as map and
ped files. The map file was based on the CanFam3.1. ref-
erence, Annotation Release 104.
Quality control
We carried out the quality control in stages for within-
breed and across-breed association analyses. Initially
there were 1607 samples and 52 SNPs before the QC
steps. The QC thresholds for the breed-specific data
were: 0.90 for per ID and per SNP call rates, 0.05 for the
minor allele frequency (MAF), and 0.0001 for the cut-off
p-value in check for Hardy-Weinberg Equilibrium
(HWE) (done in controls only). The resulting breed-
specific data is described in Table 4. SNP-specific
failures to meet the QC criteria are presented in
Additional file 1.
The QC for the across-breed data was done in two
steps in PLINK. The first QC step was done at the
breed-level before merging, with the following thresh-
olds: 0.90 for per ID and per SNP call rates, 0.0001 for
the cut-off p-value in check for HWE check in controls.
MAF cut-off level was set to zero in this initial step, be-
cause some SNPs that might not pass the MAF thresh-
old within a breed, might however pass it in the across-
breed cohort. Subsequently, the SNPs and individuals
that passed this initial QC step were merged into the
across-breed data set. The final QC with the MAF cut-
off threshold at 0.05 was then executed over the whole
across-breed data, which left us 46 SNPs and 1572 sam-
ples. However, one Bernese Mountain dog and one
Golden Retriever had hip scores of B/D (left hip/right
hip) and they were excluded from the analysis, because
we could not rule out the possibility of unilateral CHD
induced by an injury or other environmental factor.
Therefore, we finally had 1570 dogs in our analyses, of
which 751 were cases, 819 were controls, and 666 were
males and 904 were females.
Association analysis
Before the analyses we tested the quality-controlled SNP
data for possible batch effects in R with the glm-
function. This was done because the genotyping was
executed in two batches. We did not observe any signifi-
cant batch effects. The within-breed analyses were
carried out with the --assoc (X2-test of allele frequen-
cies) or with --logistic (logistic regression) functions in
PLINK, with age at radiographing as covariate in the lo-
gistic model (--assoc cannot use covariates).
As the SNPs in the study are a strongly selected and
small subset of all the SNPs in the genome, the quantifi-
cation of inflation is a challenge. QQ-plots were used to
assess the overall fit of the alternative models and to se-
lect between them (Additional file 3). The QQ-plot is a
more representative proxy for the fit of the model than
the lambda value by PLINK which is based on the ratio
of single (median) value of the test variable.
Some inflation of the test statistics in both analysis
methods was observed in three breeds (see Additional
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file 3, plots A–D and O–P): Finnish Lapphund, Golden
Retriever, and Labrador Retriever. We did not attempt
to quantify or control the stratification in these breeds
by PCA as it is not expected to work when the number
of markers is small and the effect of any single marker is
expected to be low [47] as is the case in our study.
Odds ratios and their 95% confidence intervals were
calculated in PLINK using the default settings and the
function --ci. PLINK assigns the less frequent allele as
the minor allele that increases the risk when the odds ra-
tio is greater than one.
We used 2x2xK (K = 11) Cochran-Mantel-Haenszel
(CMH) statistics for the across-breed analysis. CMH
is a standard test for a stratified case-control analysis.
This was carried out in PLINK with the function
--mh and with breed clusters defined with the
--within function. Odds ratios and the respective 95%
confidence intervals were automatically calculated by
PLINK. The CMH test assumes homogeneity of the
odds ratios between strata (breeds in our case), and
violation of this assumption may lead to false positive
associations [48]. Therefore, we used --homog func-
tion in PLINK to check if any of the SNPs demon-
strating association in the CMH test, would violate
the homogeneity assumption; all associated SNPs
passed the homogeneity test. All permutation analyses
(using 10,000 permutations) within and across breeds
were executed with the max(T) permutation proced-
ure in PLINK with the function -- mperm 10,000. We
used a fixed seed (--seed 873,051,416) generated in
Unix shell with “date +%N” to ensure reproducible
results in all of the permutation analyses.
STRING analysis
We used STRING (Search tool for retrieval for inter-
acting genes/proteins) (V11.0) [15] to carry out a
pathway analysis of the candidate gene sets, which we
acquired from our association analyses. All genes
from within 1Mb from the variant that demonstrated
significant association to CHD were listed and then
used as an input for the STRING Multiple proteins
search. The used candidate gene sets are listed in the
Additional file 4. The STRING database was queried
with 272 canine genes but seven genes (TMEM244,
STRA6L, FOXE1, RPS13, SERGEF, ESPNL, and FAB172B)
were not found. In addition, U6 and CNKSR3 were not re-
covered in the expected chromosome and were discarded.
Thus, the STRING network for the positional candidate
genes consisted 263 nodes (https://version-11-0.string-db.
org/cgi/network.pl?networkId=5Sqk4IV9gi5b). We also
performed an additional search with a combined set of
neddylation pathway associated genes from Tables 3 and
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Additional file 1. List of markers used in the validation study. 52
selected markers with their position in CanFam3.1 are listed. From the
original publications the following details are presented: marker ID,
associated phenotype, raw and corrected P value, and the cohort size
and represented breeds. Regarding the current study, the breeds for
which the QC failed are indicated as well as the ssID’s for the markers
that passed the QC.
Additional file 2. Reference, alternative, major and minor alleles, and
genotype frequencies for the 23 validated SNPs in the across-breed and
within-breed studies.
Additional file 3. Quantile-Quantile plots of the within-breed associ-
ation analyses. The image shows breed-wise comparisons of P-values
(−log10) from a logistic regression model (logistic) or basic association
analysis (X2 test; assoc).
Additional file 4. Candidate gene sets for the STRING (V11.0) pathway
analysis. Two lists are provided: set of candidate genes from the across-
breed association analysis (N = 41), and a set of candidate genes from the
within-breed association analyses (N = 261). Total number of unique
genes in the analyses is 272. Each of the listed genes are located max-
imum ±1Mb from a SNP that demonstrated significant association to
CHD in one of the analyses.
Additional file 5. Reactome pathway R-CFA-983169 on Class I MHC me-
diated antigen processing & presentation bridges the clusters of neddyla-
tion pathway associated genes (ASB7, PSMC6, FBXO10, DCAF10, ASB4,
ASB18, COPS8, UBE2F, ASB1, FBXW8, FBXO21, WSB2) and the NOX3/MMP2/
MMP9/TRIO-associated genes (CYBA, MAPK14, MMP2, MMP9, NCF1, NCF2,
NCF4, NOX3, NOXA1, NTN1, RAC1, TRIO, VCAM1) from our previous studies
on German Shepherds. Genes belonging to R-CFA-983169 are marked
red. For a high resolution image and the original analysis, see: https://
version-11-0b.string-db.org/cgi/network?networkId=bPwtieGk6WuV.
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